Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ryngo 1-23
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Ryngo 1-23 is a small molecule dynamin activator that stimulates actin-dependent dynamin oligomerization and promotes dynamin GTPase activity. Despite its role as an activator of the dynamin protein, it paradoxically functions as an inhibitor of clathrin-mediated endocytosis (CME), specifically blocking the uptake of transferrin in cells such as dendritic cells. It is primarily utilized as a research tool to investigate the mechanisms of membrane fission and vesicle trafficking. Chemically, it is a bis-tyrphostin derivative and is available as a research reagent.
- Other names
- dynamin activatorRyngo(2E,2'E)-N,N'-1,3-Propanediylbis[2-cyano-3-(3,4,5-trihydroxyphenyl)-2-propenamide]CAS 171674-76-3CAS171674-76-3CAS-171674-76-3
02
Targets
DNM2 (Dynamin 2)
Beyond the preview
Go deeper on Ryngo 1-23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ryngo 1-23.